Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) Institutional Ownership
CUSIP: 92337R101
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
213
Shares (Excl. Options)
74,007,590
Price
$50.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Class A Common Stock, par value $0.001 per share
- Symbol
- VERA on Nasdaq
- Shares outstanding
- 72,325,000
- Price per share
- $40.23
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 74,007,590
- Total reported value
- $3,747,901,575
- % of total 13F portfolios
- 0.01%
- Share change
- +8,497,924
- Value change
- +$504,714,925
- Number of holders
- 213
- Price from insider filings
- $40.23
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share is tracked under CUSIP 92337R101.
- 213 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 213 to 15 between Q4 2025 and Q1 2026.
- Reported value moved from $3,747,901,575 to $6,118,802.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 213 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92337R101?
CUSIP 92337R101 identifies VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92337R101:
Significant Owners of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.9% | $134,640,000 | 5,610,000 | Avoro Capital Advisors LLC | 31 Dec 2024 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.7% | +33% | $276,595,072 | +$90,918,550 | 5,461,988 | +49% | T. Rowe Price Associates, Inc. | 31 Dec 2025 |
| Deep Track Capital, LP | 5.5% | $176,892,640 | 3,921,362 | Deep Track Capital, LP | 04 Mar 2026 | |||
| VANGUARD GROUP INC | 5% | $180,805,107 | 3,570,401 | The Vanguard Group | 31 Dec 2025 | |||
| Kynam Capital Management, LP | 5.4% | $83,444,698 | 3,426,887 | Kynam Capital Management, LP | 30 Jun 2025 | |||
| Flynn James E | 5.2% | $75,299,151 | 3,348,117 | Deerfield Mgmt, L.P. | 06 Jun 2025 | |||
| FMR LLC | 4.1% | $146,139,596 | 2,885,853 | FMR LLC | 31 Dec 2025 | |||
| Sofinnova Venture Partners X, L.P. | 4% | $128,465,927 | 2,847,837 | Dr. Maha Katabi ("Katabi") | 10 Dec 2025 | |||
| Point72 Asset Management, L.P. | 1.7% | $51,344,964 | 1,229,525 | Point72 Asset Management, L.P. | 25 Mar 2026 |
As of 31 Dec 2025, 213 institutional investors reported holding 74,007,590 shares of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA). This represents 102% of the company’s total 72,325,000 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.1% | 5,888,888 | -5.2% | 2.9% | $298,213,288 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.6% | 5,461,976 | +49% | 0.03% | $276,595,000 |
| BlackRock, Inc. | 6.7% | 4,825,519 | +14% | 0% | $244,364,280 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 5.6% | 4,059,695 | +11% | 2.6% | $205,582,955 |
| VANGUARD GROUP INC | 4.9% | 3,570,401 | +12% | 0% | $180,805,107 |
| Kynam Capital Management, LP | 4.7% | 3,433,051 | -15% | 11% | $173,849,703 |
| Eversept Partners, LP | 4.2% | 3,072,304 | +9.4% | 8.7% | $155,581,475 |
| FMR LLC | 4% | 2,885,853 | +1.5% | 0.01% | $146,139,597 |
| Deep Track Capital, LP | 3.9% | 2,821,135 | 3.3% | $142,862,276 | |
| Sofinnova Investments, Inc. | 3.9% | 2,793,987 | 0% | 6.1% | $141,487,502 |
| STATE STREET CORP | 3.7% | 2,676,600 | +15% | 0% | $135,543,024 |
| Integral Health Asset Management, LLC | 2.5% | 1,800,000 | +5.9% | 4.6% | $91,152,000 |
| Point72 Asset Management, L.P. | 2.4% | 1,738,385 | +37% | 0.14% | $88,031,816 |
| Bellevue Group AG | 2.3% | 1,698,152 | 1.6% | $85,994,417 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,444,925 | +9.3% | 0% | $73,185,024 |
| Pictet Asset Management Holding SA | 1.9% | 1,392,421 | -3.2% | 0.07% | $70,512,199 |
| Holocene Advisors, LP | 1.8% | 1,307,393 | 0.14% | $66,206,382 | |
| ALLIANCEBERNSTEIN L.P. | 1.7% | 1,218,657 | +2217% | 0.02% | $61,712,790 |
| GOLDMAN SACHS GROUP INC | 1.5% | 1,120,780 | +48% | 0.01% | $56,756,299 |
| Woodline Partners LP | 1.4% | 1,000,279 | +36% | 0.2% | $50,654,129 |
| First Light Asset Management, LLC | 1.2% | 869,676 | +72% | 3.4% | $44,040,393 |
| Tri Locum Partners LP | 1.1% | 805,689 | -32% | 5.3% | $40,800,091 |
| BRAIDWELL LP | 1.1% | 784,742 | +66% | 1.3% | $39,739,335 |
| CITADEL ADVISORS LLC | 1.1% | 777,488 | -52% | 0.03% | $39,371,992 |
| AMERICAN CENTURY COMPANIES INC | 1% | 732,699 | +3.4% | 0.02% | $37,103,945 |
Institutional Holders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 152,096 | $6,118,802 | -$365,505 | $40.23 | 15 |
| 2025 Q4 | 74,007,590 | $3,747,901,575 | +$504,714,925 | $50.64 | 213 |
| 2025 Q3 | 65,067,827 | $1,890,768,857 | +$37,111,876 | $29.06 | 173 |
| 2025 Q2 | 63,893,006 | $1,505,324,602 | +$17,298,219 | $23.56 | 171 |
| 2025 Q1 | 62,915,975 | $1,512,522,250 | -$90,036,678 | $24.02 | 176 |
| 2024 Q4 | 62,912,622 | $2,660,465,176 | +$389,856,746 | $42.29 | 177 |
| 2024 Q3 | 53,519,938 | $2,365,061,400 | -$1,769,076 | $44.20 | 172 |
| 2024 Q2 | 52,988,211 | $1,917,110,562 | +$57,678,654 | $36.18 | 169 |
| 2024 Q1 | 51,298,718 | $2,212,007,022 | +$474,171,827 | $43.12 | 157 |
| 2023 Q4 | 41,345,437 | $635,880,813 | +$44,778,975 | $15.38 | 93 |
| 2023 Q3 | 39,258,779 | $538,195,352 | +$9,620,413 | $13.71 | 84 |
| 2023 Q2 | 38,127,621 | $611,912,465 | +$42,587,635 | $16.05 | 76 |
| 2023 Q1 | 37,354,429 | $289,749,836 | +$137,641,985 | $7.76 | 69 |
| 2022 Q4 | 21,331,464 | $412,748,829 | -$7,253,468 | $19.35 | 57 |
| 2022 Q3 | 21,539,667 | $459,015,997 | +$19,117,341 | $21.31 | 55 |
| 2022 Q2 | 20,391,008 | $277,615,038 | +$7,846,841 | $13.61 | 49 |
| 2022 Q1 | 19,483,745 | $457,319,068 | +$130,146,246 | $23.49 | 49 |
| 2021 Q4 | 14,054,730 | $374,899,000 | +$10,499,638 | $26.72 | 37 |
| 2021 Q3 | 14,710,587 | $252,433,000 | +$4,174,540 | $17.35 | 30 |
| 2021 Q2 | 14,513,290 | $186,104,000 | +$186,104,000 | $13.25 | 21 |